CD8A and neoplasm: Further, noninvasive identification methods to assess response at the early stage of ICI treatment were recommended using pre-treatment circulating tumor DNA and peripheral CD8+ T-cell levels to predict the durable clinical benefit of patients based on whole-exome sequencing and RNA-sequencing in non-small cell lung cancer [118].